Coiled Therapeutics (LSE:COIL), formerly Roquefort Therapeutics, reported its first interim results since acquiring a licence to the cancer drug candidate AO-252 and moving to AIM. It highlighted an 80% clinical benefit rate in the twice-daily cohort of a Phase I trial and held £5.1m of cash at 30 June 2026.

What was announced

Coiled Therapeutics plc (LSE:COIL), which is also traded on the US OTCQB market, published interim results for the six months to 30 June 2026 on 28 September 2026.

On 27 March 2026 the company, then Roquefort Therapeutics plc, completed the Acquisition of an exclusive worldwide licence to AO-252 from Coiled Therapeutics, Inc., moved from the Main Market to AIM, changed its name and completed a fundraise. AO-252 is described as a first-in-class, orally administered inhibitor of TACC3. The initial consideration of £31.875m was settled entirely in shares, through 318.75 million consideration shares at 10p each. A further 127.5 million performance shares are payable if the company's Market Capitalisation is sustained at £60m, £90m and £120m for 30 consecutive days, with a Fair Value of about £9.0m recognised. The licence was capitalised as an intangible asset of £43.4m.

The fundraise raised £8.5m gross, and about £7.78m net, mainly through placing and subscription shares at 10p.

The numbers

The net loss for the half was £3,851,679, compared with £490,147 in the first half of 2025. R&D costs rose to £1,257,095 from £142,956, administrative expenses to £831,624 from £347,750, and the period included £1,128,977 of share-based payments and £632,161 of one-off relisting and acquisition costs. The loss per share was 1.66p (H1 2025: 3.32p), after a share reorganisation on 26 March 2026 that consolidated every ten shares into one and then split each into a 1p ordinary share and a 9p deferred share.

Cash was £5,099,604 at 30 June 2026, compared with £78,054 at 31 December 2025.

The clinical data

In the Phase I trial of AO-252 (NCT06136884), data reported in April 2026 showed an 80% clinical benefit rate in the twice-daily dosing cohort, compared with 40% for once-daily dosing. Patients were heavily pre-treated, with a median of five prior lines of therapy. The company said 80% of evaluable twice-daily patients had tumour stabilisation or regression lasting at least six months, no serious adverse effects were reported and the maximum tolerated dose had not been reached. These are early-stage results from a small Phase I study, and the number of patients in each cohort is not stated in the interim summary.

Because the original tablet gave suboptimal exposure at higher doses, the company introduced a lipid-based softgel formulation. The first patient was dosed in August 2026, and by September the 120mg twice-daily and 160mg once-daily cohorts, six patients in total, were fully enrolled.

Executive Chairman Dr Sotirios Stergiopoulos said the result, with the safety profile seen so far and the fact that the maximum tolerated dose has not been reached, provides a foundation for the next stage of AO-252's clinical development.

What to watch next

The company expects up to about 30 patients to be dosed with the new formulation by the end of 2026, with initial safety and pharmacokinetic data before year-end. In 2027 it expects to generate a preliminary efficacy dataset with a safety database of about 50 patients, alongside biomarker work and Phase II planning, including expansion in ovarian and prostate cancer. These timelines are company expectations.

Board changes during the period included the appointments of Dr Stergiopoulos and chief executive Sridhar Vempati on 27 March, Dr Andrew Dean as a non-executive director on 7 May and former Silence Therapeutics chief executive Craig Tooman as an independent non-executive director on 25 June.